13G Filing: Adage Capital Management and Stemline Therapeutics Inc (STML)

Item 3.

IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

(a)

¨

Broker or dealer registered under Section 15 of the Act;

(b)

¨

Bank as defined in Section 3(a)(6) of the Act;

(c)

¨

Insurance company as defined in Section 3(a)(19) of the Act;

(d)

¨

Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)

¨

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)

¨

An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);

(g)

¨

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)

¨

A savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act;

(i)

¨

A church plan that is excluded from the definition
of an investment company under Section 3(c)(14) of the Investment Company Act;

(j)

¨

A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

(k)

¨

Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
specify the type of institution: Not applicable.

Item 4.		OWNERSHIP
	A.	Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
			(a)	Amount beneficially owned: 1,460,014
			(b)	Percent of class: 5.78%. The percentage set forth in this Schedule 13G is calculated based upon the 25,280,024 shares of Common Stock reported to be issued and outstanding as of August 8, 2017 as reflected in the Company’s Form 10-Q for the quarterly period ended June 30, 2017, filed with the Securities and Exchange Commission on August 8, 2017.

Page 8 of 12 – SEC Filing

Item 2(d).	TITLE OF CLASS OF SECURITIES
	Common Stock, par value $0.0001 per share (the “Common Stock“).

Item 2(e).	CUSIP NUMBER
	85858C107